Therefore, emerging research suggests that combination therapies of monoclonal anti-CXCL8 antibodies or CXCR1/CXCR2 antagonists with standard anti-tumor (immuno)therapy can tackle the tumor immune escape and provide further benefit in anti-tumor treatment. The gene discussed is CXCR2; the disease is neoplasm.